ReviewThe lancet. HIV2021
The case for an HIV cure and how to get there.
Review in The lancet. HIV, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.Gene therapy · 2026Article
- Article
- Delay, Doubt and Dollars: Exploring Delay and Probability Discounting of Free and Paid HIV Vaccines among Sexual and Gender Minorities.AIDS and behavior · 2026Article
- Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026Article
- Characterising concerns and misinformation shaping global HIV vaccine confidence and demand: a structured literature search and content analysis.BMJ global health · 2026Review
- 'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa.HIV research & clinical practice · 2025Article
- Understanding of HIV cure research in a rural community with high prevalence: the case of uMkhanyakude district, KwaZulu-Natal, South Africa.AIDS research and therapy · 2025Article
- Trends and disparities in human immunodeficiency virus and chronic liver disease mortality in the United States: A nationwide analysis.The Journal of international medical research · 2025Article
- "A cure might help, but it won't erase it all": a qualitative study of policy challenges and priorities for long-term survivors of HIV in the United States.Journal of the International AIDS Society · 2025Article
- Treatment of Advanced HIV in the Modern Era.Drugs · 2025Review
- HIV Cure: How Far We Have Come?Indian journal of microbiology · 2025Review
- The expected impact of a cure for HIV among people with HIV and key populations.Communications medicine · 2025Article
- Model-based evaluation of the impact of a potential HIV cure on HIV transmission dynamics.Nature communications · 2025Article
- The utility of integrating nanopore sequencing into routine HIV-1 drug resistance surveillance.Microbial genomics · 2025Review
- Meeting Summary for Keystone Symposia on HIV Cure: Antiretroviral Therapy (ART)-Free Control of HIV Infection in Durban, South Africa, 2025.Pathogens & immunity · 2025Article
- Impact of an analytical treatment interruption on partners and family members of trial participants in Durban, South Africa: a qualitative study.Frontiers in public health · 2025Article
- Article
- mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy.Frontiers in bioengineering and biotechnology · 2025Review
- Comparisons of Correlates of Viral Suppression Among Adults Living With HIV/AIDS in Tanzania: Analysis With and Without Including Survey Designs.AIDS research and treatment · 2025Article
- Research Toward a Cure for Perinatal HIV.Clinics in perinatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.